The mRNA platform market holds significant opportunities, driven by advancements in LNP delivery systems, codon optimization, and synthetic biology tools like CRISPR-Cas9. These innovations support ...

Moderna's advanced logistics tech tackles temperature challenges, minimizes shipping risks, and ensures critical medical products reach their destination safely.

Moderna voluntarily pressed pause on its request to license its vaccine candidate, mRNA-1083 — which combines vaccines for seasonal influenza and covid and is intended for people over 50 — until it ...

Article originally published by. FE fundinfo is not responsible for its content or accuracy and may not share the author’s views. News and research are not personal recommendations to deal. All ...

New research demonstrates how specially engineered bacteria taken orally can operate as a delivery system for vaccines and antiviral therapies.

An experimental evaluation of the risk of influenza transmission from contaminated objects finds that viable virus was rarely ...

Today vaccine maker Moderna announced it voluntarily pulled its licensing submission for the combination seasonal ...

Novavax's full FDA approval for NUVAXOVID is a transformative milestone, unlocking a $175M Sanofi payment and validating ...

A San Diego biotech company is helping top research labs develop mRNA vaccines, including a vaccine for some types of cancer. Jaime Chambers reports. STORY: fox5sandiego.com ...

Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 7% in the afternoon session after the FDA announced new ...

Greggs (LON:GRG) jumps 8% after strong revenue growth Diploma rises over 15% after lifting guidance FTSE 100 has extended gains above 8700 The FTSE 100 is rising for a fourth straight session, ...